MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
AIkido Pharma Total Current Liabilities 2011-2026 | AIKI
Annual Total Current Liabilities AIkido Pharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 1.61 M | 1.79 M | 1.06 M | 877 K | 750 K | 1.15 M | 2.58 M | 2.67 M | 4.46 M | 1.23 M | 1.5 M | 731 K | 893 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.46 M | 731 K | 1.64 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aligos Therapeutics
ALGS
|
21.2 M | $ 8.64 | 8.07 % | $ 85.4 M |  USA |
 |
I-Mab
IMAB
|
576 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | USA |
 |
Applied Therapeutics
APLT
|
71.2 M | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
158 M | $ 21.36 | 4.86 % | $ 998 M | USA |
 |
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | USA |
 |
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
163 M | $ 1.47 | 5.0 % | $ 378 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
36.6 M | - | - | $ 28.6 M | USA |
 |
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 2.92 | - | $ 4.81 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
47.6 M | $ 4.19 | 2.7 % | $ 448 M | USA |
 |
Aravive
ARAV
|
22.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
130 M | $ 24.12 | -0.37 % | $ 3.07 B | USA |
 |
Celldex Therapeutics
CLDX
|
51 M | $ 32.59 | 1.09 % | $ 2.16 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
73.4 M | $ 1.47 | -1.34 % | $ 391 M |  Britain |
 |
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Cidara Therapeutics
CDTX
|
49.6 M | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | Israel |
 |
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
12.4 M | $ 4.25 | 8.35 % | $ 286 B | Britain |
 |
Allena Pharmaceuticals
ALNA
|
15.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
301 M | $ 2.22 | 2.3 % | $ 461 M | USA |
 |
Baudax Bio
BXRX
|
21.5 M | - | 0.59 % | $ 63 K | USA |
 |
Cabaletta Bio
CABA
|
50.2 M | $ 3.2 | 2.24 % | $ 322 M | USA |
 |
Alpine Immune Sciences
ALPN
|
58 M | - | - | $ 2.17 B | USA |
 |
CymaBay Therapeutics
CBAY
|
36.8 M | - | - | $ 3.45 B | USA |
 |
Aileron Therapeutics
ALRN
|
6.18 M | - | 10.36 % | $ 9.8 M | USA |